Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label randomized study of HH-003 in chronic hepatitis D virus infection
CTR20231354Phase 2Completed
- Sponsor
- Huahui Health
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Libevitug in hepatitis D (HDV), sponsored by Huahui Health. Started Jun 2023; status: completed.
02
Drugs
Libevitug
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on CTR20231354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231354.